I think we can do better at the CEO position than someone who steals and lies. That is a non starter for me. Some folks do not have as high an ethical standard as I do for leaders.
It looks like the 13 D effort has not been successful and the market is none too pleased.
I disagree with your Unequivocal opinion. After all, your assessment merely belongs to you and no objective measures were cited in support of same. It is moot at this point.
Assuming FDA was going to play hardball with CYDY’s submission to begin with, Nader was the not an ideal character to shepherd the BLA through the process, given his lack of pharma skills, communication issues and lack of attention to detail.
With the back drop of the RTF and FDA rebuke these characteristics will be negative force multipliers for the BLA re-submission. FDA will be all over the resubmission with a fine tooth comb and that does not bode well for a Nader led submission. Can any successful Nader submission to government bodies be identified? Note: FDA said CYDY needs to learn how to properly craft trial designs.
Now the agenda is revealed and opinions evolve with no rational case for the conclusion. Hatred for Nader is pretty easy to evoke. He lies, steals and has epically failed in his efforts to commercialize LL. The group as coalesced around the desperate need to get a qualified CEO before it is too late.
I have made a pretty crystal clear case, based on the record, that it is improbable for one man to be competent and have epically failed to the degree of Nader unless these failures are purposeful.
The record shows his failures and character, these are not opinions. Cash and time are running out.
AI
Market Data 
Markets 
